Corat Therapeutics
Hamburg, Germany· Est. 2018
Recombinant human virus-neutralizing antibodies are the active component of the immunotherapy
Private Company
Total funding raised: $5.7M
About
Recombinant human virus-neutralizing antibodies are the active component of the immunotherapy
AntibodiesBiologics
Funding History
2Total raised:$5.7M
Grant$1.2MJun 15, 2021
Seed$4.5MSep 15, 2020